Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin + electrolyte solution refers to a fluid resuscitation regimen being evaluated for the treatment of sepsis-induced hypotension in patients with cirrhosis and acute-on-chronic liver failure (ACLF). This intervention, specifically studied at the Post Graduate Institute of Medical Education and Research, Chandigarh, involves the administration of 20% human albumin (at doses of 0.5-1 g/kg) in conjunction with balanced salt solutions (such as Plasmalyte). Albumin acts as a colloid to increase plasma oncotic pressure and expand intravascular volume, while the electrolyte solution provides crystalloid-based volume replacement and maintains acid-base balance. The regimen aims to improve hemodynamic stability and fluid responsiveness in critically ill liver disease patients, who often exhibit baseline hypoalbuminemia and altered hemodynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albumin + electrolyte solution.